ArticleCurrent microbiology2025
Lactiplantibacillus plantarum MTCC 25433 and Quercetin Blend Ameliorate Benzo[a]pyrene-Induced Gut Dysregulation in a Murine Model.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Benzo[a]pyrene (B[a]P), a carcinogenic food contaminant, is implicated in colonic abnormalities, including colorectal cancer. This study evaluated the synergistic potential of a novel synbiotic blend of Lactiplantibacillus plantarum MTCC 25433 (9 log CFU/d) and quercetin (25 mg/kg/d) against B[a]P-induced gut dysregulation in Swiss albino mice. Oral B[a]P exposure (50 mg/kg, twice weekly for 28 days) disrupted the intestinal homeostasis, enhancing lipid peroxidation (+ 44.1%), proinflammatory cytokines levels (TNF-α: + 69.6%, IL-6: + 52.9%), inflammatory transcription factors (Nf-κB: 1.92-fold, Foxa2: 2.92-fold) and mucin expression (Muc-2: 2.9-fold), and perturbed gut barrier integrity (Occludin: 0.61-fold, Cldn-4: 0.14-fold). The synbiotic blend exhibited superior efficacy compared to MTCC 25433 or quercetin alone, mitigating MDA (- 32%), TNF-α (- 66%), IL-6 (- 59%), Nf-κB: - 38%, Foxa2: - 51%, Muc-2 (- 57%), Occludin (+ 129%) and Cld-4 (+ 352%) levels and further resulted in enhanced B[a]P fecal excretion (29.5 to 182 μg/g). Two-way ANOVA analysis confirmed synergistic interactions specifically for reductions in adipose tissue B[a]P levels, metabolic enzyme expression (Cyp1b1), gut barrier integrity (Cldn-4), and microbiome modulation, notably Firmicutes, Lachnospiraceae, Clostridium and Ruminococcus, along with enhanced butyrate concentrations. Histopathological analysis confirmed the protective effects of a synbiotic blend against B[a]P-mediated adipocyte disruption and necrosis in the hepatic and intestinal tissues. Principal component analysis also supported its synergistic efficacy in alleviating B[a]P toxicity. Overall, these findings demonstrated the potent anti-inflammatory, antioxidant and gut-modulating potential of the synbiotic blend, suggesting its potential as a promising dietary approach for mitigating the harmful effects of the food contaminant, B[a]P.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.